{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:52:41Z","timestamp":1782492761934,"version":"3.54.5"},"reference-count":37,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T00:00:00Z","timestamp":1310083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p>Information regarding rituximab monotherapy with eight weekly infusions for relapsed or refractory indolent B cell non\u2010Hodgkin lymphoma (B\u2010NHL), in particular for patients pretreated with rituximab, is limited. To evaluate the efficacy and safety of eight doses of rituximab monotherapy, 52 patients with relapsed or refractory indolent B\u2010NHL were enrolled in the present study. Forty of 45 eligible patients (89%) had follicular lymphoma and 24 (53%) were at intermediate or high risk group according to the Follicular Lymphoma International Prognostic Index. The median number of prior chemotherapy regimens was 1 (range 1\u20137). At the median follow\u2010up of 12.2\u2003months, the overall response rate (ORR), complete response rate (%CR), and median progression\u2010free survival (PFS) were 69% (95% confidence interval [CI] 53%\u201382%), 47% (95% CI 32%\u201362%), and 15.6\u2003months (95% CI 10.6\u2013 months), respectively. In the 33 patients pretreated with rituximab, the ORR, %CR, and median PFS were inferior compared with values for the 12 patients who had not received rituximab previously (64%<jats:italic>vs<\/jats:italic> 83% for ORR; 39%<jats:italic>vs<\/jats:italic> 67% for %CR; and 13.8 <jats:italic>vs<\/jats:italic> 17.5\u2003months for median PFS, respectively). All mild\u2010to\u2010moderate infusion\u2010related toxicities were reversible. Grade 3\/4 non\u2010hematologic adverse events occurred in six of the 52 patients. Two patients developed Grade 4 late\u2010onset neutropenia and a decrease (&gt;50%) in serum immunoglobulin was observed in six patients. In conclusion, rituximab monotherapy with eight weekly infusions is effective in relapsed patients with indolent B\u2010NHL, with acceptable toxicities, including in patients pretreated with rituximab; however, careful monitoring is recommended for infections associated with late\u2010onset neutropenia and hypogammaglobulinemia. (University Hospital Medical Information Network no. UMIN000002974.) (<jats:italic>Cancer Sci<\/jats:italic> 2011; 102: 1698\u20131705)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2011.02001.x","type":"journal-article","created":{"date-parts":[[2011,6,6]],"date-time":"2011-06-06T11:20:22Z","timestamp":1307359222000},"page":"1698-1705","source":"Crossref","is-referenced-by-count":18,"title":["Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non\u2010Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study"],"prefix":"10.1111","volume":"102","author":[{"given":"Kensei","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiko","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Nawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the IDEC\u2010C2B8 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01703.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1398"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf155"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_7_18_2","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier B","year":"1998","journal-title":"Blood"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh176"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389119525"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02981940"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.2307\/2530297"},{"key":"e_1_2_7_24_2","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.9313"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265313133"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jjco.a039642"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_7_31_2","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel L","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_7_32_2","first-page":"1860","article-title":"Report of the Committee on Hodgkin\u2019s Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13440"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2011.02001.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2011.02001.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T20:54:01Z","timestamp":1697403241000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2011.02001.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,8]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1349-7006.2011.02001.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02001.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,8]]}}}